Literature DB >> 31741119

Arterial Hypertension, Aldosterone, and Atrial Fibrillation.

Teresa M Seccia1, Brasilina Caroccia1, Giuseppe Maiolino1, Maurizio Cesari1, Gian Paolo Rossi2.   

Abstract

PURPOSE: Atrial fibrillation is the most common sustained arrhythmia, with a prevalence of 1-2% in the general population and over 15% in people older than 80 years. Due to aging of the population it imposes an increasing burden on the healthcare system because of the need for life-long pharmacological treatment and the associated increased risk of heart failure and hospitalization. Hence, identification of the factors that predispose to atrial fibrillation it is of utmost relevance. RECENT
FINDINGS: Several conditions exist that are characterized by inappropriately high levels of aldosterone, mostly primary aldosteronism and the severe or drug-resistant forms of arterial hypertension. In these forms, aldosterone can cause prominent target organ damage, mostly in the heart, vasculature, and kidney. This review examines the experimental data and clinical evidences that support a link between hyperaldosteronism and atrial fibrillation, and how this knowledge should lead to a change in our management of the hypertensive patients presenting with atrial fibrillation.

Entities:  

Keywords:  Aldosterone; Arrhythmia; Atrial fibrillation; Hypertension

Mesh:

Substances:

Year:  2019        PMID: 31741119     DOI: 10.1007/s11906-019-1001-4

Source DB:  PubMed          Journal:  Curr Hypertens Rep        ISSN: 1522-6417            Impact factor:   5.369


  46 in total

1.  Effects of aldosterone on transient outward K+ current density in rat ventricular myocytes.

Authors:  J P Bénitah; E Perrier; A M Gómez; G Vassort
Journal:  J Physiol       Date:  2001-11-15       Impact factor: 5.182

Review 2.  Arterial Hypertension, Atrial Fibrillation, and Hyperaldosteronism: The Triple Trouble.

Authors:  Teresa M Seccia; Brasilina Caroccia; Gail K Adler; Giuseppe Maiolino; Maurizio Cesari; Gian Paolo Rossi
Journal:  Hypertension       Date:  2017-04       Impact factor: 10.190

Review 3.  Primary aldosteronism: cardiovascular, renal and metabolic implications.

Authors:  Gian-Paolo Rossi; Leonardo A Sechi; Gilberta Giacchetti; Vanessa Ronconi; Pasquale Strazzullo; John W Funder
Journal:  Trends Endocrinol Metab       Date:  2008-03-07       Impact factor: 12.015

Review 4.  Cellular and molecular electrophysiology of atrial fibrillation initiation, maintenance, and progression.

Authors:  Jordi Heijman; Niels Voigt; Stanley Nattel; Dobromir Dobrev
Journal:  Circ Res       Date:  2014-04-25       Impact factor: 17.367

5.  Conditional mineralocorticoid receptor expression in the heart leads to life-threatening arrhythmias.

Authors:  Antoine Ouvrard-Pascaud; Yannis Sainte-Marie; Jean-Pierre Bénitah; Romain Perrier; Christelle Soukaseum; Aurelie Nguyen Dinh Cat; Anne Royer; Khai Le Quang; Flavien Charpentier; Sophie Demolombe; Fatima Mechta-Grigoriou; Ahmed T Beggah; Pierre Maison-Blanche; Marie-Edith Oblin; Claude Delcayre; Glenn I Fishman; Nicolette Farman; Brigitte Escoubet; Frederic Jaisser
Journal:  Circulation       Date:  2005-06-06       Impact factor: 29.690

6.  Raised plasma aldosterone and natriuretic peptides in atrial fibrillation.

Authors:  Ulrik Dixen; Lasse Ravn; Christian Soeby-Rasmussen; Anders Wallin Paulsen; Jan Parner; Erik Frandsen; Gorm B Jensen
Journal:  Cardiology       Date:  2006-09-12       Impact factor: 1.869

7.  Prospective appraisal of the prevalence of primary aldosteronism in hypertensive patients presenting with atrial flutter or fibrillation (PAPPHY Study): rationale and study design.

Authors:  G P Rossi; T M Seccia; V Gallina; M L Muiesan; L Leoni; M Pengo; F Ragazzo; P Caielli; A Belfiore; G Bernini; F Cipollone; S Cottone; C Ferri; G Giacchetti; G Grassi; C Letizia; M Maccario; O Olivieri; G Palumbo; D Rizzoni; E Rossi; L Sechi; M Volpe; F Mantero; A Morganti; A C Pessina
Journal:  J Hum Hypertens       Date:  2012-06-21       Impact factor: 3.012

8.  The mineralocorticoid receptor promotes fibrotic remodeling in atrial fibrillation.

Authors:  Daniel Lavall; Christian Selzer; Pia Schuster; Matthias Lenski; Oliver Adam; Hans-Joachim Schäfers; Michael Böhm; Ulrich Laufs
Journal:  J Biol Chem       Date:  2014-01-27       Impact factor: 5.157

9.  Body mass index predicts plasma aldosterone concentrations in overweight-obese primary hypertensive patients.

Authors:  Gian Paolo Rossi; Anna Belfiore; Giampaolo Bernini; Bruno Fabris; Graziella Caridi; Claudio Ferri; Gilberta Giacchetti; Claudio Letizia; Mauro Maccario; Massimo Mannelli; Gaetana Palumbo; Anna Patalano; Damiano Rizzoni; Ermanno Rossi; Achille C Pessina; Franco Mantero
Journal:  J Clin Endocrinol Metab       Date:  2008-04-29       Impact factor: 5.958

10.  Adrenalectomy Lowers Incident Atrial Fibrillation in Primary Aldosteronism Patients at Long Term.

Authors:  Gian Paolo Rossi; Giuseppe Maiolino; Alberto Flego; Anna Belfiore; Giampaolo Bernini; Bruno Fabris; Claudio Ferri; Gilberta Giacchetti; Claudio Letizia; Mauro Maccario; Francesca Mallamaci; Maria Lorenza Muiesan; Massimo Mannelli; Aurelio Negro; Gaetana Palumbo; Gabriele Parenti; Ermanno Rossi; Franco Mantero
Journal:  Hypertension       Date:  2018-02-26       Impact factor: 10.190

View more
  6 in total

Review 1.  Impact of Primary Aldosteronism in Resistant Hypertension.

Authors:  Konstantinos Stavropoulos; Konstantinos P Imprialos; Dimitrios Patoulias; Alexandra Katsimardou; Michael Doumas
Journal:  Curr Hypertens Rep       Date:  2022-04-21       Impact factor: 4.592

2.  LncRNA XIST shuttled by adipose tissue-derived mesenchymal stem cell-derived extracellular vesicles suppresses myocardial pyroptosis in atrial fibrillation by disrupting miR-214-3p-mediated Arl2 inhibition.

Authors:  Boyu Yan; Ting Liu; Chang Yao; Xinglong Liu; Qian Du; Lihua Pan
Journal:  Lab Invest       Date:  2021-08-13       Impact factor: 5.662

Review 3.  Cerebro-Cardiovascular Risk, Target Organ Damage, and Treatment Outcomes in Primary Aldosteronism.

Authors:  Xiao Lin; Muhammad Hasnain Ehsan Ullah; Xiong Wu; Feng Xu; Su-Kang Shan; Li-Min Lei; Ling-Qing Yuan; Jun Liu
Journal:  Front Cardiovasc Med       Date:  2022-02-02

Review 4.  A narrative review of non-coding RNAs in atrial fibrillation: potential therapeutic targets and molecular mechanisms.

Authors:  Lan Zhang; Xi Wang; Congxin Huang
Journal:  Ann Transl Med       Date:  2021-09

5.  Dex modulates the balance of water-electrolyte metabolism by depressing the expression of AVP in PVN.

Authors:  Wenzhi Yang; Hao Li; Zhongle Cheng; You Lu; Wuli Li; Jun Feng; Liecheng Wang; Juan Cheng
Journal:  Front Pharmacol       Date:  2022-08-23       Impact factor: 5.988

6.  Molecular mechanism of atrial remodeling in patients with aging atrial fibrillation under the expression of microRNA-1 and microRNA-21.

Authors:  Kexin Yuan; Pei Zhao; Lili Wang
Journal:  Bioengineered       Date:  2021-12       Impact factor: 3.269

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.